Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin R Farlow

Showing results (101-110 of 189) with videos related to

Pageof 19
Sort By:
Acta Neuropathologica Communications|October 31, 2018
Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [<sup>18</sup>F]Flortaucipir PETShannon L Risacher, Martin R Farlow, Daniel R Bateman, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|August 29, 2012
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's diseaseLynn M Bekris, Steve Millard, Franziska Lutz, et al.
Archives of Neurology|July 13, 2006
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognitionElaine R Peskind, Ge Li, Jane Shofer, et al.
American Journal of Nuclear Medicine and Molecular Imaging|April 13, 2016
[(11)C]PiB PET in Gerstmann-Sträussler-Scheinker diseaseKacie D Deters, Shannon L Risacher, Karmen K Yoder, et al.
Neurobiology of Aging|May 11, 2012
ADAM10 expression and promoter haplotype in Alzheimer's diseaseLynn M Bekris, Franziska Lutz, Gail Li, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
American Journal of Neurodegenerative Disease|January 29, 2015
Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriersKacie D Deters, Shannon L Risacher, Martin R Farlow, et al.
Briefings in Functional Genomics & Proteomics|June 23, 2007
Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometryValentina Gelfanova, Richard E Higgs, Robert A Dean, et al.
Alzheimer'S Research & Therapy|July 5, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 31, 2019
White matter alterations in early-stage Alzheimer's disease: A tract-specific studyQiuting Wen, Sourajit M Mustafi, Junjie Li, et al.
Pageof 19

Showing results (101-110 of 189) with videos related to

Sort By:
Pageof 19
Acta Neuropathologica Communications|October 31, 2018
Detection of tau in Gerstmann-Sträussler-Scheinker disease (PRNP F198S) by [<sup>18</sup>F]Flortaucipir PETShannon L Risacher, Martin R Farlow, Daniel R Bateman, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|August 29, 2012
Tau phosphorylation pathway genes and cerebrospinal fluid tau levels in Alzheimer's diseaseLynn M Bekris, Steve Millard, Franziska Lutz, et al.
Archives of Neurology|July 13, 2006
Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognitionElaine R Peskind, Ge Li, Jane Shofer, et al.
American Journal of Nuclear Medicine and Molecular Imaging|April 13, 2016
[(11)C]PiB PET in Gerstmann-Sträussler-Scheinker diseaseKacie D Deters, Shannon L Risacher, Karmen K Yoder, et al.
Neurobiology of Aging|May 11, 2012
ADAM10 expression and promoter haplotype in Alzheimer's diseaseLynn M Bekris, Franziska Lutz, Gail Li, et al.
Medrxiv : the Preprint Server for Health Sciences|April 2, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
American Journal of Neurodegenerative Disease|January 29, 2015
Cerebral hypometabolism and grey matter density in MAPT intron 10 +3 mutation carriersKacie D Deters, Shannon L Risacher, Martin R Farlow, et al.
Briefings in Functional Genomics & Proteomics|June 23, 2007
Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometryValentina Gelfanova, Richard E Higgs, Robert A Dean, et al.
Alzheimer'S Research & Therapy|July 5, 2024
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's DiseaseDouglas Galasko, Martin R Farlow, Brendan P Lucey, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)|August 31, 2019
White matter alterations in early-stage Alzheimer's disease: A tract-specific studyQiuting Wen, Sourajit M Mustafi, Junjie Li, et al.
Pageof 19